Medicine and Dentistry
Systemic Lupus Erythematosus
71%
Connective Tissue Disease
66%
Lupus Erythematosus
66%
Determinants of Health
33%
Rituximab
33%
Meta-Analysis
33%
Lupus Nephritis
33%
Belimumab
33%
Short Form 36
26%
Diseases
24%
Systemic Scleroderma
16%
Biological Marker
16%
Multiple Chronic Conditions
16%
Autoantibodies
13%
Hypogammaglobulinemia
9%
Glucocorticoid
9%
Diagnosis
6%
Logistic Regression Analysis
6%
Fibromyalgia
6%
Charlson Comorbidity Index
6%
Symptom
6%
Finger
5%
Complement Activation
5%
Serositis
5%
Topoisomerase
5%
Anti-dsDNA Antibodies
5%
Inflammatory Cytokine
5%
Immunology and Microbiology
Connective Tissue
100%
Systemic Lupus Erythematosus
49%
Lupus Erythematosus
33%
Undifferentiated Connective Tissue Disease
33%
Belimumab
33%
Rituximab
33%
Autoimmune Rheumatic Disease
33%
Immunoassay
33%
Systemic Scleroderma
23%
Protein Expression
22%
Autoantibodies
13%
Ro Antibody
11%
Hypogammaglobulinemia
9%
Glucocorticoid
9%
Anti-dsDNA Antibodies
6%
Complement Activation
6%
Proinflammatory Cytokine
6%
Comorbidity
6%
Regulatory T Cell
6%
Mixed Connective Tissue Disease
6%
Pharmacology, Toxicology and Pharmaceutical Science
Systemic Lupus Erythematosus
66%
Paraquat
33%
Rituximab
33%
Belimumab
33%
Remission
11%
Glucocorticoid
9%
Immunoglobulin Deficiency
9%
Immunosuppressive Agent
9%
Multiple Chronic Conditions
9%
Disease Activity
5%
Arthralgia
5%
Myalgia
5%
Disease Exacerbation
5%
Autoimmune Disease
5%
